A new study indicates ‘we can identify those that are susceptible to Alzheimer’s disease and give them this peptide [therapy] ...

A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...

Alzheimer’s disease. Anyone past the age of 50 has likely experienced a version of this predicament, euphemistically termed a ...

Recognizing the signs of mild cognitive impairment meant Di could start treatment earlier to help slow her Alzheimer's ...

Older adults with anemia had 66% higher odds of developing dementia, with those with elevated Alzheimer’s disease blood ...

The first interim safety results from a multicenter, safety surveillance study of Alzheimer's disease patients treated with ...

A new study​ finds that a simple blood test could predict Alzheimer's disease long before symptoms appear.

Researchers at UC San Diego have found that diabetes in Latino adults may be linked to higher-risk of Alzheimer's disease, as ...

Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.

Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ ...

Why do memories fade in Alzheimer's disease—and can they be restored? University of California, Irvine researchers have ...

The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein ...